Arabic Arabic English English French French German German
dark

BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH

BioCryst Pharmaceuticals, Inc. announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

White House Enlists Social Media Giants to Suppress Vaccine ‘Misinformation’

Next Post

Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada’s National Research Council

Related Posts
Total
0
Share